CosmosID is a genomic big data company focused on rapid identification of microorganisms for infectious disease diagnostics, public health surveillance, food safety inspections, pharmaceutical discovery, and microbiome analysis for health and wellness.
From a post-sequencing metagenomic sample we identify bacteria, DNA viruses, fungi, parasites, antibiotic resistance and virulence genes, and more within minutes.
With the use of our curated genome databases and both sensitivity and specificity >95% we are unmatched in our ability to detect microorganisms in metagenomic samples.
The speed and universal nature of the test, and the ability to detect both pathogens and antimicrobial resistance genes at once will improve patient outcomes, shortening the length of hospitalization and avoiding complex therapies to significantly reduce total cost of care.
"CosmosID can provide the resolution necessary for genomic sequencing of pathogens to become a reality in the shift to precision medicine."
"I have explored the microbiome of everything from the NY subway to outer space and the software analysis component is critically important. CosmosID provides a robust tool for the quantification and detection of microorganisms and antimicrobial resistance markers and we are actively using it for onsite in situ diagnostics."
"The precise strain level identification that CosmosID provides could revolutionize clinical microbiology, directing physicians towards improved and more effective treatment options."
"We first sent specimens to [CosmosID] in late October, and we are already talking to them about results, so for me that was impressive that we were able to get such fast turnaround. I was impressed by the number of species that were identified, particularly ones in lower abundance."